Nanotechnology Now - Press Release: CORRECTING and REPLACING Dr. Edward Flynn Recognized in American Physical Society Publication for His Work in Cancer Detection: Manhattan Scientifics Physicist Develops Nanotechnology Tools to Fight Breast Cancer

Home > Press > CORRECTING and REPLACING Dr. Edward Flynn Recognized in American Physical Society Publication for His Work in Cancer Detection: Manhattan Scientifics Physicist Develops Nanotechnology Tools to Fight Breast Cancer

Abstract:
The corrected release reads:

Dr. Edward R. Flynn Ph.D., founder of Senior Scientific, LLC, a company owned by Manhattan Scientifics (OTCBB: MHTX), has been prominently mentioned for his work in cancer detection in the October issue of The American Physical Society publication, APS News.

CORRECTING and REPLACING Dr. Edward Flynn Recognized in American Physical Society Publication for His Work in Cancer Detection: Manhattan Scientifics Physicist Develops Nanotechnology Tools to Fight Breast Cancer

Albuquerque, NM | Posted on October 5th, 2011

Manhattan Scientifics announced in June the acquisition of Senior Scientific LLC to commercialize the groundbreaking tools for cancer detection, diagnosis and treatment originated by new nanotechnology tools that can detect tumors and metastases much earlier than currently possible. The technology also has the capability to accurately measure the number of cancer cells in a tumor while precisely finding the tumor location. The technology can enable personalized treatment since it can identify the exact type of cancer cells present, allowing doctors to design treatments for the type and extent of cancer present.

The APS News article said, "Edward Flynn, a nuclear physicist who worked at Los Alamos National Laboratory for 38 years, saw a problem and knew his unique skill set could help conquer it. His wife was diagnosed with breast cancer and he pondered whether he could develop a better detection tool using nanoparticles and magnetic sensors. He created a technique in which a patient is injected with iron oxide nanoparticles coated with antibodies, which adhere to specific cancer cells present in a tumor. The patient is then subjected to a small magnetizing field that aligns the metal nanoparticles and when the field is discontinued, the nanoparticles emit a magnetic signal. This emitted signal is detected by superconducting quantum interference device (SQUID) sensors. The resulting signal measurement can show doctors "how many metal particles, and therefore how many cancer cells, are present, and where in the breast they are located," according to a recent article featuring Flynn by Shirley S. Wang in The Wall Street Journal."

The APS News noted that Dr. Flynn's innovation requires only a very small number of cancerous cells to be present, approximately 100,000, as opposed to several million cells needed for a mammogram. This means the system can detect a breast cancer tumor with 100% accuracy up to three years earlier than a mammogram can. Dr. Flynn's technology also greatly enhances the ability to more closely monitor the number of cancer cells.

The APS News noted that Dr. Flynn is working with Manhattan Scientifics to commercialize his technology and bring it to market.

####

About Manhattan Scientifics
Manhattan Scientifics Inc. (www.mhtx.com) is located in New Mexico, New York and Montreal. It is focused on technology transfer and commercialization of disruptive technologies in the nano medicine space. The company is presently developing commercial medical prosthetics applications for its ultra fine grain metals and plans to commercialize the cancer research work and nano medical applications developed by Senior Scientific LLC, a unit of the Company.

Forward-looking statement

This press release contains forward-looking statements, which are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. Management at Manhattan Scientifics believes that purchase of its shares should be considered to be at the high end of the risk spectrum. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.

For more information, please click here

Contacts:
Manhattan Scientifics, Inc.
www.mhtx.com
or
Senior Scientific LLC

www.seniorscientific.com
or
Public Relations:
Stanton Public Relations & Marketing
Michael Kassin
646-502-3528

or
Investor Relations:
Marvin Maslow
917-923-3300

or
U.S. & Canadian Investor Relations
Hawk Associates
Frank Hawkins
305-451-1888

or
European Contact:
Herbert Strauss
+43-316-296-316
email: herbert"at"eu-ir.com